Related Experiment Video

Updated: Feb 4, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Growth Hormone Therapy in Heart Failure

Andrea Salzano1, Alberto M Marra2, Roberta D'Assante2

  • 1Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK; Department of Translational Medical Sciences, Federico II University, School of Medicine, Via Pansini 5, Naples, 80131, Italy.

Heart Failure Clinics
|September 30, 2018
PubMed

Insights

Growth hormone (GH) deficiency is common in chronic heart failure, impacting function and outcomes. This review explores GH deficiency, its effects, and the potential of GH-replacement therapy in heart failure patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Heart Failure Research

Background:

  • Growth hormone (GH) deficiency is prevalent in chronic heart failure (CHF).
  • GH deficiency correlates with reduced functional capacity and poorer prognosis in CHF patients.
  • Animal models suggest GH treatment benefits cardiovascular parameters and survival.

Purpose of the Study:

  • To assess growth hormone (GH) deficiency in chronic heart failure (CHF).
  • To review the molecular basis, clinical impact, and therapeutic strategies for GH deficiency in CHF.
  • To discuss the evolving role of GH-replacement therapy in managing CHF.

Main Methods:

  • Review of existing literature on GH deficiency in chronic heart failure.
  • Analysis of data from animal models and clinical studies.
  • Exploration of molecular mechanisms and therapeutic outcomes.

Main Results:

  • Clinical translation of GH treatment benefits in CHF has yielded inconsistent results.
  • Understanding the molecular background of GH deficiency is crucial for effective management.
  • GH-replacement therapy presents a promising avenue for improving outcomes in CHF.

Conclusions:

  • GH deficiency is a significant comorbidity in chronic heart failure.
  • Further research is needed to clarify the role and optimize GH-replacement therapy in CHF.
  • Targeted GH therapy may offer improved functional capacity and outcomes for select CHF patients.

Keywords:
Anabolic deficiencyBiomarkerChronic heart failureGrowth hormoneHormone deficiencyIGF-1Novel therapiesOutcomes

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.5K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
329